Enlivex Therapeutics Ltd. (ENLV) Stock Analysis & Investment Frameworks
Enlivex Therapeutics Ltd. (ENLV) stock analysis on Invetso. Review Enlivex Therapeutics Ltd.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Enlivex Therapeutics Ltd. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
Enlivex Therapeutics Ltd. Key Financial Metrics
- Market Cap: $3.40M
- Revenue: $N/A
- ROE: 211.00%
- ROIC: -0.32%
- Dividend Yield: N/A
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Enlivex Therapeutics Ltd. Investment Frameworks
Invetso analyzes Enlivex Therapeutics Ltd. (ENLV) across the following frameworks:
- Enlivex Therapeutics Ltd. 10Y Growth Potential
- Enlivex Therapeutics Ltd. Scenario Analysis
- Enlivex Therapeutics Ltd. Risks & Opportunities
- Enlivex Therapeutics Ltd. Economic Moat
- Enlivex Therapeutics Ltd. Business Model
- Enlivex Therapeutics Ltd. Management
- Enlivex Therapeutics Ltd. SWOT Analysis
- Enlivex Therapeutics Ltd. Porter's 5 Forces
- Enlivex Therapeutics Ltd. PESTLE Analysis
- Enlivex Therapeutics Ltd. ESG Analysis